| 2025-10-29 |
复牌提示：
2025-10-29 09:57:00 停牌，复牌日期 2025-10-29 10:02:00
|
| 2025-10-28 |
股东大会：
将于2025-12-15召开股东大会
会议内容 ▼▲
- 1.To approve the grant of equity-based awards to Gil Efron, the Chief Executive Officer of the Company, in such amounts and with such terms and conditions as described in Proposal 1 of the Proxy Statement for the Meeting.
2.To approve the grant of equity-based awards to each of the members of the Board of Directors, in such amounts and with such terms and conditions as described in Proposal 1 of the Proxy Statement for the Meeting.
|
| 2025-10-28 |
股东大会：
将于2025-12-15召开股东大会
会议内容 ▼▲
- 1.To approve the grant of equity-based awards to Gil Efron, the Chief Executive Officer of the Company, in such amounts and with such terms and conditions as described in Proposal 1 of the Proxy Statement for the Meeting.
2.To approve the grant of equity-based awards to each of the members of the Board of Directors, in such amounts and with such terms and conditions as described in Proposal 1 of the Proxy Statement for the Meeting.
|
| 2025-10-28 |
详情>>
股本变动：
变动后总股本903.04万股
|
| 2025-03-10 |
详情>>
业绩披露：
2022年年报每股收益-2.4美元,归母净利润-2166.8万美元,同比去年增长-17.86%
|
| 2025-03-10 |
详情>>
业绩披露：
2024年年报每股收益-0.02美元,归母净利润-724万美元,同比去年增长63.58%
|
| 2025-02-28 |
股东大会：
将于2025-04-15召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Dr. Eric Rowinsky, Mr. Robert Gagnon and Mr. Ido Agmon as members of the first class of directors of the Board of Directors, to serve until the Company’s annual general meeting of shareholders to be held in 2028, and until their respective successors have been duly elected and qualified;
2.To approve the grant of equity-based awards to (a) Mr. Gil Efron, our Chief Executive Officer; and (b) each of our directors who shall serve in such capacity as of immediately following the Meeting;
3.To approve an increase in the Company’s authorized ordinary share capital and to amend the Company’s Articles of Association accordingly.
|
| 2025-02-28 |
股东大会：
将于2025-04-15召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Dr. Eric Rowinsky, Mr. Robert Gagnon and Mr. Ido Agmon as members of the first class of directors of the Board of Directors, to serve until the Company’s annual general meeting of shareholders to be held in 2028, and until their respective successors have been duly elected and qualified;
2.To approve the grant of equity-based awards to (a) Mr. Gil Efron, our Chief Executive Officer; and (b) each of our directors who shall serve in such capacity as of immediately following the Meeting;
3.To approve an increase in the Company’s authorized ordinary share capital and to amend the Company’s Articles of Association accordingly.
|
| 2024-11-15 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.02美元,归母净利润-683万美元,同比去年增长54.62%
|
| 2024-09-17 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2024-08-16 |
详情>>
业绩披露：
2024年中报每股收益-0.02美元,归母净利润-616.7万美元,同比去年增长38.43%
|
| 2024-06-26 |
股东大会：
将于2024-08-08召开股东大会
会议内容 ▼▲
- 1.The purpose of the Meeting is to approve the re-election of Mr. Issac Israel and Ms. Suzana Nahum-Zilberberg as members of the third class of directors of the Board of Directors, for a three-year term until the annual general meeting of shareholders to be held in 2027, and until their successors have been duly elected and qualified.
2.In addition, at the Meeting, representatives of the Company’s management will be available to review and discuss with shareholders the consolidated financial statements of the Company for the year ended December 31, 2023.saa.
|
| 2024-06-26 |
股东大会：
将于2024-08-08召开股东大会
会议内容 ▼▲
- 1.The purpose of the Meeting is to approve the re-election of Mr. Issac Israel and Ms. Suzana Nahum-Zilberberg as members of the third class of directors of the Board of Directors, for a three-year term until the annual general meeting of shareholders to be held in 2027, and until their successors have been duly elected and qualified.
2.In addition, at the Meeting, representatives of the Company’s management will be available to review and discuss with shareholders the consolidated financial statements of the Company for the year ended December 31, 2023.saa.
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-0.09美元,归母净利润-1988万美元,同比去年增长8.25%
|
| 2023-08-22 |
详情>>
业绩披露：
2023年中报每股收益-0.05美元,归母净利润-1001.6万美元,同比去年增长7.54%
|
| 2023-05-01 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To approve the election of Simcha Rock as a member of the second class of directors of the Board of Directors, for a three-year term until the annual general meeting of shareholders to be held in 2026, and until his successor is duly elected and qualified.
2.To approve the grant of equity-based awards to (i) each of our directors (other than Isaac Israel, who also serves as Acting Chief Executive Officer of the Company) who shall serve in such capacity as of immediately following the Meeting; and (ii) Isaac Israel, a director and Acting Chief Executive Officer of the Company.
3.To approve the terms of engagement of Mr. Isaac Israel as our Acting Chief Executive Officer.
4.To approve the payment to Mr. Isaac Israel of the discretionary portion of his 2021 and 2022 annual bonuses for his former service as our Chief Executive Officer.
5.To approve the payment to Dr. Eric Rowinsky, the Chairman of the Company’s Board of Directors, of an additional fee for service as Chairman of the Company’s Medical and Clinical Committee.
6.To approve and adopt an amended and restated Compensation Policy for executive officers and directors.
7.To approve the reappointment of Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, as the Company’s independent registered public accountants for a period of three years until the annual general meeting of shareholders to be held in 2026.
|
| 2023-05-01 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To approve the election of Simcha Rock as a member of the second class of directors of the Board of Directors, for a three-year term until the annual general meeting of shareholders to be held in 2026, and until his successor is duly elected and qualified.
2.To approve the grant of equity-based awards to (i) each of our directors (other than Isaac Israel, who also serves as Acting Chief Executive Officer of the Company) who shall serve in such capacity as of immediately following the Meeting; and (ii) Isaac Israel, a director and Acting Chief Executive Officer of the Company.
3.To approve the terms of engagement of Mr. Isaac Israel as our Acting Chief Executive Officer.
4.To approve the payment to Mr. Isaac Israel of the discretionary portion of his 2021 and 2022 annual bonuses for his former service as our Chief Executive Officer.
5.To approve the payment to Dr. Eric Rowinsky, the Chairman of the Company’s Board of Directors, of an additional fee for service as Chairman of the Company’s Medical and Clinical Committee.
6.To approve and adopt an amended and restated Compensation Policy for executive officers and directors.
7.To approve the reappointment of Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, as the Company’s independent registered public accountants for a period of three years until the annual general meeting of shareholders to be held in 2026.
|
| 2022-07-18 |
股东大会：
将于2022-08-25召开股东大会
会议内容 ▼▲
- 1.To approve the election of Dr. Eric Rowinsky, Ido Agmon and Robert Gagnon as members of the first class of directors of the Board of Directors, each for a three-year term until the annual general meeting of shareholders to be held in 2025, and until their respective successors are duly elected and qualified;
2.To approve the grant of equity-based awards to each of our directors, provided that in the case of Dr. Eric Rowinsky, Ido Agmon and Robert Gagnon, the grant shall be subject to their re-election as a director at the Meeting under Proposal 1;
3.To approve the terms of engagement of Mr. Gil Efron as our new Chief Executive Officer;
4.To approve the terms of engagement of Mr. Isaac Israel, a director, for service as an advisor to the Company, and the payment to Mr. Israel of the discretionary portion of his 2021 and 2020 annual bonuses for his former service as our Chief Executive Officer;
5.To approve the payment to Dr. Eric Rowinsky, the Chairman of our Board of Directors, of an additional fee for service as Chairman of our Medical and Clinical Committee.
|
| 2021-12-22 |
股东大会：
将于2021-12-22召开股东大会
会议内容 ▼▲
- 1.To approve the election of Isaac Israel, Suzana Nahum-Zilberberg and Ori Hershkovitz as members of the third class of directors of the Board of Directors, each for a three-year term until the annual general meeting of shareholders to be held in 2024, and until their respective successors are duly elected and qualified;
2.To approve the issuance by the Company of a letter of exemption and letter of indemnification to Robert Gagnon, as a member of our Board of Directors;
3.To approve the grant of equity-based awards to each of (a) Dr. Eric Rowinsky, the Chairman of our Board of Directors, (b) Robert Gagnon, a member of our Board of Directors, (c) Suzana Nahum-Zilberberg, a member of our Board of Directors, subject to her re-election as a director at the Meeting, and (d) Ori Hershkovitz, a director nominee, subject to his election as a director at the Meeting;
4.To approve an amendment to the annual bonus terms of Mr. Isaac Israel, our Chief Executive Officer and a director;
5.To approve the payment of the discretionary portion of the 2020 annual bonus to Mr. Isaac Israel, our Chief Executive Officer and a director, and the payment of such portion of the bonus in the form of our American Depositary Shares (“ADSs”).
|
| 2021-12-22 |
股东大会：
将于2021-12-29召开股东大会
会议内容 ▼▲
- 1.To approve the election of Isaac Israel, Suzana Nahum-Zilberberg and Ori Hershkovitz as members of the third class of directors of the Board of Directors, each for a three-year term until the annual general meeting of shareholders to be held in 2024, and until their respective successors are duly elected and qualified;
2.To approve the issuance by the Company of a letter of exemption and letter of indemnification to Robert Gagnon, as a member of our Board of Directors;
3.To approve the grant of equity-based awards to each of (a) Dr. Eric Rowinsky, the Chairman of our Board of Directors, (b) Robert Gagnon, a member of our Board of Directors, (c) Suzana Nahum-Zilberberg, a member of our Board of Directors, subject to her re-election as a director at the Meeting, and (d) Ori Hershkovitz, a director nominee, subject to his election as a director at the Meeting;
4.To approve an amendment to the annual bonus terms of Mr. Isaac Israel, our Chief Executive Officer and a director;
5.To approve the payment of the discretionary portion of the 2020 annual bonus to Mr. Isaac Israel, our Chief Executive Officer and a director, and the payment of such portion of the bonus in the form of our American Depositary Shares (“ADSs”).
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-10-22 |
股东大会：
将于2020-12-03召开股东大会
会议内容 ▼▲
- 1.To approve the election of Steven Steinberg and Simcha Rock as members of the second class of directors of the Board of Directors, each for a three-year term until the annual general meeting of shareholders to be held in 2023, and until their respective successors are duly elected and qualified;
2.To approve an amendment to each of the Company’s Memorandum of Association and Articles of Association to provide for the change in the Company’s name to “Purple Biotech Ltd.” or to such other name that contains the word “Purple” as the management of the Company shall determine and as shall be approved by the Israel Registrar of Companies;
3.To approve the reappointment of Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, as the Company’s independent registered public accountants for a period of three years until the annual general meeting of shareholders to be held in 2023.
|
| 2020-08-21 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2020-07-01 |
股东大会：
将于2020-08-06召开股东大会
会议内容 ▼▲
- 1.To approve an increase of our registered and authorized ordinary share capital and corresponding amendments to our articles of association and our memorandum of association;
2.To approve an amendment to the Kitov Pharma Ltd. 2016 Equity-Based Incentive Plan to increase the aggregate number of ordinary shares reserved thereunder in order to be able to award options that qualify as incentive stock options for U.S. tax purposes;
3.To approve an amended and restated Compensation Policy for our executive officers and directors;
4.To approve the grants of equity-based awards to each of (a) Isaac Israel, our Chief Executive Officer and a director, (b) Dr. Eric Rowinsky, the Chairman of our Board of Directors, and (c) the other members of our Board of Directors.
|
| 2019-11-12 |
股东大会：
将于2019-12-23召开股东大会
会议内容 ▼▲
- 1.To review the Company’s Financial Statements and Annual Report for the year ended December 31, 2018.
2.To review the compensation paid by the Company during 2018 to Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, the independent public accountants of the Company.
3.To approve nominees for appointment as members of the first class of directors on the Board of Directors of the Company, each to serve for a three-year term until the 2022 Annual General Meeting, and until their successors have been duly elected.
4.To approve the terms of office and employment of the appointed directors.
5.To transact such other business as may properly come before the Meeting
|
| 2019-04-01 |
股东大会：
将于2019-04-29召开股东大会
会议内容 ▼▲
- 1.To approve the transactions and share issuances by the Company which are to be made by the Company in connection with the Company’s transactions for the acquisition of FameWave Ltd. and the simultaneous investment in the Company by certain shareholders of FameWave Ltd.
2.To approve the transactions and share issuances by the Company which would be made by the Company in connection with the Company’s possible transactions for investment in the Company by additional institutional investors.
3.To approve certain amendments to the terms of office and compensation of members of the Company’s Board of Directors, including the grant of equity-based incentive compensation.
4.To transact such other business as may properly come before the Meeting.
|
| 2018-11-09 |
股东大会：
将于2018-12-19召开股东大会
会议内容 ▼▲
- 1.To review the Company’s Financial Statements and Annual Report for the year ended December 31, 2017.
2.To review the compensation paid by the Company during 2017 to Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, the independent public accountants of the Company.
3.To approve an addition to the Company’s amended and restated articles of association, with respect to establishing exclusive forums for certain litigation matters involving the Company.
4.To re-appoint each of Messrs. Isaac Israel and Simcha Rock, and Ms. Revital Stern-Raff to the Board of Directors, as members of the third class of directors, each to serve for a three-year term until the 2021 Annual General Meeting, and until their successors have been duly elected.
5.To approve an amendment to the terms of office and employment of Dr. John Paul Waymack, the Chairman of the Board of Directors and Chief Medical Officer of the Company.
6.To approve an amendment to the terms of office and employment of Mr. Isaac Israel a member of the Board of Directors and Chief Executive Officer of the Company.
7.To approve the terms of office and employment of Mr. Simcha Rock a member of the Board of Directors, with respect to his services as a consultant of the Company.
8.To approve a 1-for-20 reverse share split of the Company’s ordinary shares, effective on the date to be announced by the Company, and to approve the applicable amendments to each of the Company’s Memorandum of Association and Amended and Restated Articles of Association to reflect such reverse split.
9.To transact such other business as may properly come before the Meeting
|
| 2017-10-27 |
股东大会：
将于2017-12-04召开股东大会
会议内容 ▼▲
- 1.To review the Company’s Financial Statements and Annual Report for the year ended December 31, 2016.
2.To review the compensation paid by the Company during 2016 to Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, the independent public accountants of the Company, and to approve their re-appointment as the independent public accountants of the Company for three years until the 2020 Annual General Meeting, and to authorize the Audit Committee of the Board of Directors of the Company to fix the compensation of said auditors in accordance with the scope and nature of their services.
3.To vote on a proposal to a change of the Company's name to Kitov Biopharma Ltd. or such similar name containing the name “Kitov” as determined by the Company's management and approved by the Israeli Registrar of Companies, and approve the applicable amendments to the Company's Memorandum of Association and Articles of Association to reflect such name change (the change of the Company’s name will be effective only following the approval and authorization of the Israeli Registrar of Companies).
4.To re-appoint each of Messrs. Steven Steinberg, Ido Agmon and Ran Tzror to the Board of Directors, as members of the second class of directors, each to serve for a three-year term until the 2020 Annual General Meeting, and until their successors have been duly elected.
5.To transact such other business as may properly come before the Meeting
|
| 2017-06-08 |
股东大会：
将于2017-07-12召开股东大会
会议内容 ▼▲
- 1.To approve an increase in the number of ordinary shares reserved for the grant of awards under the kitov pharmaceuticals holdings ltd. 2016 equity-based incentive plan to qualify for incentive stock options for us tax purposes.
2.To approve the new compensation policy of the company.
3.To approve letters of exemption and indemnity granted by the company to each of certain directors at the company, as well as their inclusion under the current d&o policy of the company.
4.To approve the revised directors and officers insurance coverage for all current and future office holders of the company.
5.To approve an amendment to the terms of office and employment of dr. John paul waymack, the chairman of the board of directors and chief medical officer of the company, including the grant of equity-based incentive compensation.
6.To approve an amendment to the terms of office and employment of mr. Isaac israel, a member of the board of directors and chief executive officer of the company, including the grant of equity-based incentive compensation.
7.To approve an amendment to the terms of office and employment of mr. Simcha rock, a member of the board of directors and chief financial officer of the company, including the grant of equity-based incentive compensation.
8.To approve an amendment to the terms of office and employment of each of the non-executive directors of the company, including the grant of equity-based incentive compensation.
|
| 2016-11-02 |
股东大会：
将于2016-12-12召开股东大会
会议内容 ▼▲
- 1.To review the Company’s Financial Statements and Annual Report for the year ended December 31, 2015.
2.To review the compensation paid by the Company during 2015 to Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, the independent public accountants of the Company.
3.To approve the letters of exemption and indemnity granted by the Company to each of certain directors at the Company: Mr. Steven Steinberg, Mr. Ido Agmon and Ms. Leah Bruck.
4.To re-appoint each of Drs. Paul Waymack and Alain Zeitoun to the Board of Directors, as members of the first class of directors, each to serve for a three-year term until the 2019 Annual General Meeting, and until their successors have been duly elected.
5.To approve proposals for certain amendments to the Company’s Amended and Restated Articles of Association and to the Company’s Memorandum of Association, as follows:
a.to approve the increase of the Company’s registered Ordinary Share capital to 5,000,000,000 Ordinary Shares of no par value each;
b.to approve the addition to the Company’s registered share capital of 1,000,000,000 Preferred Shares of no par value each;
c.to approve that the organizational supervisor for our internal auditor will be the General Manager of the Company, and the annual or periodic work plan shall be presented to our Audit Committee of the Board of Directors for its review and approval;
d.to approve certain miscellaneous amendments to the articles, which clarify that the Board may issue shares of the Company which shall be dormant upon issue, and that the provisions concerning officeholder insurance coverage, exculpation and indemnification are prospective in nature and will incorporate any future revisions to applicable law governing such matters.
6.To transact such other business as may properly come before the Meeting.
|
| 2016-05-20 |
股东大会：
将于2016-06-27召开股东大会
会议内容 ▼▲
- 1. To approve the Kitov Pharmaceuticals Holdings Ltd. 2016 Equity-Based Incentive Plan to qualify for incentive stock options for US tax purposes.
2. To approve an amendment to the terms of office and compensation of Mr. Isaac Israel, a member of the Board of Directors and Chief Executive Officer of the Company, including the grant of equity-based incentive compensation.
3. To approve the grant of equity-based incentive compensation to Mr. Simcha Rock, a member of the Board of Directors and Chief Financial Officer of the Company.
4. To approve an amendment to the terms of office and compensation of Dr. John Paul Waymack, the Chairman of the Board of Directors and Chief Medical Officer of the Company, including the grant of equity-based incentive compensation.
|
| 2016-01-25 |
股东大会：
将于2016-03-02召开股东大会
会议内容 ▼▲
- 1.To approve a proposal to replace the Company’s Articles of Association in their entirety.
2.To re-appoint the following persons to the Board of Directors, each to serve for an additional term and until their successors have been duly elected: Dr. John Paul Waymack, Isaac Israel, Simcha Rock, and Philip Serlin.
3.To appoint Yair Katzir to serve as a director for an initial term and until his successor has been duly elected, and to approve his remuneration and benefits for service as a director.
4.To review the compensation paid by the Company during 2014 to Somekh Chaikin, Certified Public Accountants (Israel), a member of KPMG International, the independent public accountants of the Company.
5.To review the Company’s Financial Statements and Annual Report for the year ended December 31, 2014, and to transact such other business as may properly come before the Meeting.
|